SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunologic therapies, today announced that Dan Faga, Chief Executive Officer, and Paul Lizzul, AnaptysBio’s Chief Medical Officer, will represent the company in a fireside chat at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022 at 3:30 PM ET / 12:30 PM PT.
A live audio webcast of the presentation will be available on the investors section of the AnaptysBio website at https://ir.anaptysbio.com/events. A replay of the webcast will be available for 90 days after the event.
AnaptysBio is a clinical-stage biotechnology company focused on providing innovative therapies in immunology. The Company’s proprietary anti-inflammatory pipeline includes its anti-IL-36R antibody, imsidolimab, previously called ANB019, for the treatment of dermatological inflammatory diseases, including generalized pustular psoriasis, or GPP, and moderate hidradenitis suppurativa to severe; rosnilimab, its program of anti-PD-1 agonists, previously called ANB030, for the treatment of moderate to severe alopecia areata; and its anti-BTLA agonist program, ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. AnaptysBio’s antibody pipeline was developed using its proprietary Somatic Hypermutation, or SHM, platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed several therapeutic antibodies as part of an immuno-oncology collaboration with GSK, including an antagonist anti-PD-1 antibody (JEMPERLI (dostarlimab-gxly) GSK4057190), an antagonist anti-TIM-3 antibody (cobolimab , GSK4069889) and an anti-LAG-3 antagonist antibody (GSK4074386).
Copyright 2022 GlobeNewswire, Inc.